Covid-19 roundup: Pfiz­er/BioN­Tech launch Omi­cron-spe­cif­ic vac­cine tri­al; UK to re­cruit thou­sands more for mol­nupi­ravir study

Pfiz­er and BioN­Tech an­nounced Tues­day that they’ve ini­ti­at­ed a clin­i­cal study to eval­u­ate the safe­ty, tol­er­a­bil­i­ty and im­muno­genic­i­ty of an Omi­cron-tar­get­ed vac­cine can­di­date in healthy adults 18 through 55 years of age, al­though it re­mains un­clear when, if ever, that vac­cine might be nec­es­sary.

Draw­ing on some of the par­tic­i­pants from the com­pa­nies’ Phase III boost­er study, the tri­al will en­roll up to 1,420 par­tic­i­pants and eval­u­ate three groups of healthy adults up to the age of 55, in­clud­ing one group who re­ceived 2 dos­es of the Pfiz­er vac­cine and will get one shot of the Omi­cron-spe­cif­ic boost­er, one group that re­ceived three dos­es of the Pfiz­er vac­cine and will get one of the Omi­cron-based vac­cines, and then a third group re­ceiv­ing three dos­es of the Omi­cron-based vac­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER